Tim Walbert, Horizon Therapeutics CEO (via YouTube)

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Am­gen, J&J’s Janssen and Sanofi are all in talks to ac­quire Hori­zon Ther­a­peu­tics, the rare dis­ease biotech dis­closed late Tues­day.

Hori­zon con­firmed “high­ly pre­lim­i­nary dis­cus­sions” with those com­pa­nies re­gard­ing a po­ten­tial buy­out of­fer af­ter the Wall Street Jour­nal re­port­ed takeover in­ter­est.

Al­though the com­pa­ny — which com­mands a mar­ket cap of close to $18 bil­lion — em­pha­sized that “there can be no cer­tain­ty that any of­fer will be made for the Com­pa­ny,” shares $HZNP still surged 31% in af­ter-hours trad­ing to near $103, bring­ing it to the point where it start­ed the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.